LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) shares traded down 8.5% on Monday . The company traded as low as $18.81 and last traded at $19.38. 351,716 shares were traded during mid-day trading, an increase of 104% from the average session volume of 172,211 shares. The stock had previously closed at $21.18.
Analyst Ratings Changes
Several analysts have issued reports on LENZ shares. TD Cowen initiated coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They set a "buy" rating and a $60.00 price objective on the stock. Citigroup boosted their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $41.67.
Read Our Latest Stock Analysis on LENZ
LENZ Therapeutics Stock Up 9.3 %
The firm has a market capitalization of $558.02 million, a PE ratio of -4.25 and a beta of 0.43. The business's 50-day moving average price is $23.68 and its 200-day moving average price is $27.10.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, analysts anticipate that LENZ Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.
Institutional Trading of LENZ Therapeutics
Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in LENZ Therapeutics in the 4th quarter worth about $29,000. KLP Kapitalforvaltning AS acquired a new position in LENZ Therapeutics during the 4th quarter valued at $46,000. Tower Research Capital LLC TRC boosted its holdings in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after purchasing an additional 1,151 shares during the period. Virtus ETF Advisers LLC acquired a new stake in LENZ Therapeutics in the 4th quarter worth $67,000. Finally, GAMMA Investing LLC raised its position in shares of LENZ Therapeutics by 5,254.1% during the first quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after buying an additional 5,727 shares during the last quarter. Institutional investors and hedge funds own 54.32% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Recommended Stories
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
